ClinicalTrials.gg
CompletedNCT00481871Updated Jan 7, 2020Results posted

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

A Phase 1/2 interventional study of Pralatrexate Injection and Gemcitabine Hydrochloride in Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma and Peripheral T-cell Lymphoma, sponsored by Acrotech Biopharma Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-07.

Primary conditionHodgkin DiseaseRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hodgkin Disease
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Hodgkin Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing gemcitabine in Hodgkin Disease — 3 open to participants now, 3 under way, none of them phase 3. Gemcitabine · Hodgkin Disease.

Enrollment
4th of 33
119 · median 46
Started
2007
with 1 other
Phase 1/2
7 of 34
none open now
Registered
18th of 34
by date
Lead sponsor
1 of 34
Acrotech Biopharma Inc.

Among the 34 studies testing gemcitabine in Hodgkin Disease, this one is the 4th largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2007, is one of 7 in phase 1/2, and was the 18th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

3 of the 34 studies testing gemcitabine in Hodgkin Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing gemcitabine in Hodgkin Disease, or all of them as a file.
02

Study summary

This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma (HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's macroglobulinemia.

This study is being done to find doses of the combination of pralatrexate and gemcitabine with vitamin B12 and folic acid that can be safely given to patients with these types of lymphoma and explore the effectiveness of the treatment.

03

Conditions studied

  • Relapsed or Refractory Lymphoproliferative Malignancies
  • Hodgkin's Lymphoma
  • Peripheral T-cell Lymphoma
  • B-cell Lymphoma
  • Waldenstrom's Macroglobulinemia

Keywords

  • Lymphoproliferative malignancies
  • Lymphoma
  • Hodgkin's lymphoma (HL)
  • Non-Hodgkin's lymphoma (NHL)
  • PTCL
  • T/NK-cell leukemia/lymphoma
  • T-cell lymphoma/leukemia (HTLV 1+)
  • Angioimmunoblastic T-cell lymphoma
  • Blastic NK lymphoma
  • Anaplastic large cell lymphoma
  • T/NK-cell lymphoma
  • Enteropathy-type intestinal lymphoma
  • Hepatosplenic T-cell lymphoma
  • Extranodal peripheral T/NK-cell lymphoma
  • Subcutaneous panniculitis T-cell lymphoma
  • Transformed mycosis fungoides
  • PDX
  • Pralatrexate
  • Gemcitabine
  • Gemzar
  • Vitamin B12
  • Folic acid
04

In context

Hodgkin Disease Reclassified

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

This study's enrollment of 119 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.

Browse Hodgkin Disease studies →

Lead sponsor

Acrotech Biopharma Inc. is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Compared within Hodgkin Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 1: Histologically/ confirmed lymphoproliferative . Patients with Hodgkin lymphoma (HL) or non-HL are eligible, with exceptions per exclusion criteria.
  • Phase 2a: Histologically/cytologically confirmed HL, peripheral T-cell lymphoma (PTCL), or B-cell lymphoma including Waldenström's macroglobulinemia, with exceptions per exclusion criteria.
  • Progression of disease (PD) after at least 1 prior treatment (any number of prior therapies allowed). PD after last prior treatment and recovered from toxic effects of prior therapy. Patients treated with an FDA-approved monoclonal antibody therapy may be enrolled at any time after the therapy if they have PD.
  • PTCL patients must have received single-agent pralatrexate as a prior therapy.
  • performance status ≤ 2.
  • Adequate blood, liver and kidney function per laboratory tests.
  • Has taken 1 mg daily oral folic acid for at least 7 days prior to planned start of pralatrexate and received 1 mg vitamin B12 intramuscularly within 10 weeks of the planned start of pralatrexate.
  • Females of must practice a medically acceptable regimen from first dose until at least 30 days after last dose of pralatrexate and have a negative serum pregnancy test within 14 days prior to the first day of study treatment. (defined as greater than 12 months since last menses) and surgically sterilized females do not require this test.
  • Males who are not surgically sterile must practice a medically acceptable contraceptive regimen from first dose until at least 90 days after last dose of pralatrexate.
  • Give written .

Exclusion criteria

Exclusion Criteria:

  • Phase 1

    1. B-cell: lymphoplasmacytic lymphoma (± Waldenström's macroglobulinemia); plasma cell myeloma/plasmacytoma; hairy cell leukemia.
  • Phase 2a

    1. PTCL: precursor T/Natural Killer (NK) neoplasms, with the exception of blastic NK lymphoma; T-cell prolymphocytic leukemia; T-cell large granular lymphocytic leukemia; mycosis fungoides (MF), except transformed MF; Sézary syndrome; primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis.
    2. B-cell: plasma cell myeloma/plasmacytoma; hairy cell leukemia.
  • HL or diffuse large B-cell lymphoma patients who are candidates for high dose therapy and stem cell transplantation (SCT) and for whom it is a standard curative option.
  • Active concurrent (except non melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, must be disease free for at least 5 years.
  • Congestive heart failure Class III/IV.
  • Uncontrolled hypertension.
  • (HIV)- positive diagnosis with CD4 less than 100 or detectable viral load within past 3 months and receiving anti-retroviral therapy.
  • or C virus with detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy.
  • Central nervous system disease.
  • Undergone an allogeneic SCT.
  • Patients with disease refractory to peripheral blood SCT, or who have relapsed less than 100 days since an autologous or peripheral blood SCT.
  • Active uncontrolled infection, underlying medical condition including unstable heart disease, or other serious illness impairing the ability to receive protocol treatment.
  • Major surgery within 2 weeks of planned start of treatment.
  • Receipt of any conventional chemotherapy or radiation therapy (encompassing greater than 10% of bone marrow) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the study.
  • Receipt of systemic within 7 days of study treatment, unless on a continuous dose of no more than 10 mg/day of prednisone for at least 1 month.
  • Use of drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the study.
  • Received a monoclonal antibody within 3 months without evidence of PD.
  • Previous exposure to pralatrexate and/or gemcitabine if discontinued due to treatment-related toxicity.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Pralatrexate & Gemcitabine - Sequential Days

    Drug: Pralatrexate Injection · Drug: Gemcitabine Hydrochloride · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

  • Experimental
    Pralatrexate & Gemcitabine - Same Day

    Drug: Pralatrexate Injection · Drug: Gemcitabine Hydrochloride · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

Interventions

  • Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.

    Also known as: FOLOTYN, PDX, Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin

  • Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions. Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.

    Also known as: Gemcitabine, Gemzar®, Eli Lilly and Company, Gemcitabine Hydrochloride (HCl) for Injection

  • Dietary supplementVitamin B12

    1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.

    Also known as: Cyanocobalamin

  • Dietary supplementFolic Acid

    1 mg orally Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.

    Also known as: Vitamin B9, Folate, Folacin

07

What researchers measure

Primary outcomes

  1. Objective Responses Assessed by International Workshop Criteria (IWC)

    Number of participants who achieved an objective response. Objective response was defined as a tumor response assessment of either complete response (CR) or partial response (PR) and was determined only for patients with measurable disease at baseline. A tumor response assessment reported by IWC without PET was used for any analyses in cases where an IWC+PET evaluation was not done.

    Time frame: Assessed every 8 weeks (+/- 1 week) for Phase II and no less than every 3 cycles for Phase I

Secondary outcomes

  1. Duration of Response

    Duration of response was defined as the number of days between the date of first tumor response assessment of objective response to the time of the first tumor response assessment of progressive disease (PD) or death due to any cause (date of first PD assessment or death - date of first objective response assessment + 1)

    Time frame: Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study

  2. Progression-free Survival (PFS) Time

    PFS time was calculated as the number of days from study day 1 to the date of PD or death, regardless of cause (date of PD or death - study day 1 + 1).

    Time frame: Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study

08

Results

Posted Sep 18, 2012

Participant flow

Patients were enrolled between May 2007 and July 2010 across 16 study sites, all in the United States.

Participant flow — Overall Study
MilestonePhase 1 Group A - Dose FindingPhase 1 Group B - Dose FindingPhase 1 Group C - Dose FindingPhase 2 Group BPhase 2 Group C
Started710183834
Completed710173834
Not completed00100
Withdrew: Progressive disease - pt withdrew00100

Outcome measures

PrimaryObjective Responses Assessed by International Workshop Criteria (IWC)

Number of participants who achieved an objective response. Objective response was defined as a tumor response assessment of either complete response (CR) or partial response (PR) and was determined only for patients with measurable disease at baseline. A tumor response assessment reported by IWC without PET was used for any analyses in cases where an IWC+PET evaluation was not done.

Time frame:
Assessed every 8 weeks (+/- 1 week) for Phase II and no less than every 3 cycles for Phase I
Reported as:
Number · participants
Objective Responses Assessed by International Workshop Criteria (IWC)
participantsPhase 1Phase 2 - Group BPhase 2 - Group C
Objective Responses Assessed by International Workshop Criteria (IWC)857
SecondaryDuration of Response

Duration of response was defined as the number of days between the date of first tumor response assessment of objective response to the time of the first tumor response assessment of progressive disease (PD) or death due to any cause (date of first PD assessment or death - date of first objective response assessment + 1)

Time frame:
Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study
Reported as:
Median · days
Duration of Response
daysPhase 1Phase 2 - Group BPhase 2 - Group C
Duration of Response174 (35 to 288)210 (57 to 210)170 (59 to 178)
SecondaryProgression-free Survival (PFS) Time

PFS time was calculated as the number of days from study day 1 to the date of PD or death, regardless of cause (date of PD or death - study day 1 + 1).

Time frame:
Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study
Reported as:
Median · days
Progression-free Survival (PFS) Time
daysPhase 1Phase 2 - Group BPhase 2 - Group C
Progression-free Survival (PFS) Time53.0 (49.0 to 106.0)59.0 (52.0 to 99.0)54.0 (45.0 to 89.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1—18/35 (51.4%)35/35 (100%)
Phase 2 - Group B—13/38 (34.2%)38/38 (100%)
Phase 2 - Group C—16/34 (47.1%)34/34 (100%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventPhase 1Phase 2 - Group BPhase 2 - Group C
pyrexiaGeneral disorders2/354/387/34
dyspnoeaRespiratory, thoracic and mediastinal disorders0/350/384/34
cellulitisInfections and infestations3/351/381/34
pneumoniaInfections and infestations3/351/382/34
renal failure acuteRenal and urinary disorders0/352/382/34
hypoxiaRespiratory, thoracic and mediastinal disorders0/350/382/34
neutropeniaBlood and lymphatic system disorders0/350/382/34
stomatitisGastrointestinal disorders0/350/382/34
hydronephrosisRenal and urinary disorders0/350/382/34
dehydrationMetabolism and nutrition disorders0/350/382/34
Most frequent other events
Showing 10 of 127
Most frequent other events
EventPhase 1Phase 2 - Group BPhase 2 - Group C
fatigueGeneral disorders25/3518/3815/34
pyrexiaGeneral disorders23/3518/3815/34
nauseaGastrointestinal disorders15/3524/3821/34
anaemiaBlood and lymphatic system disorders19/3514/389/34
stomatitisGastrointestinal disorders16/359/3812/34
neutropeniaBlood and lymphatic system disorders16/3514/388/34
thrombocytopeniaBlood and lymphatic system disorders14/3516/388/34
diarrhoeaGastrointestinal disorders13/3511/388/34
constipationGastrointestinal disorders10/3510/3812/34
vomitingGastrointestinal disorders12/3510/389/34

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 1 - Group APhase 1 - Group BPhase 1 - Group CPhase 2 - Group BPhase 2 - Group CTotal
<=18 years000000
Between 18 and 65 years2710242871
>=65 years53814636
Age, Continuous
Age, Continuous(years)Phase 1 - Group APhase 1 - Group BPhase 1 - Group CPhase 2 - Group BPhase 2 - Group CTotal
Mean67.6 ± 1552.4 ± 1857.4 ± 1757.9 ± 1653.2 ± 1556.4 ± 16.1
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 - Group APhase 1 - Group BPhase 1 - Group CPhase 2 - Group BPhase 2 - Group CTotal
Female434171442
Male3714212065
Region of Enrollment
Region of Enrollment(participants)Phase 1 - Group APhase 1 - Group BPhase 1 - Group CPhase 2 - Group BPhase 2 - Group CTotal
United States710183834107
09

Study locations

15 sites
  • University of California at Los Angeles
    Los Angeles, California 90095-7077, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • University of Chicago Hospital
    Chicago, Illinois 60637, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115-6013, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • The Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New York University Hospital
    New York, New York 10016, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10017, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Cancer Therapy & Research Center
    San Antonio, Texas 78229-4427, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of May 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2007
First posted
Jun 4, 2007
Start
May 2007
Primary completionActual
May 2011
CompletionActual
Aug 2011
Results first posted
Sep 18, 2012
Last update
Jan 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00481871
Responsible party
Sponsor
First posted
Jun 4, 2007
Start date
May 2007
Primary completion
May 2011
Completion
Aug 2011
Results posted
Sep 18, 2012
Last update
Jan 7, 2020

Study contacts

Michael Saunders, MD
study director · Spectrum Pharmaceuticals, Inc
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pralatrexate · Gemcitabine · Vitamin B 12 · Folic Acid

Start the discussion